aztreonam

(redirected from Cayston)
Also found in: Dictionary, Medical, Wikipedia.
  • noun

Synonyms for aztreonam

an antibiotic (trade name Azactam) used against severe infections

References in periodicals archive ?
Cayston offers a much-needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics.
Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa and Cayston are registered trademarks of Gilead Sciences, Inc.
In the study, 268 patients were randomized to receive Cayston or tobramycin inhalation solution over a 24-week treatment period.
Adverse reactions occurring in more than 5 percent of patients treated with Cayston compared to placebo, respectively, in Phase III studies were cough (54 percent versus 51 percent), nasal congestion (16 percent versus 12 percent), wheezing (16 percent versus 10 percent), pharyngolaryngeal pain (12 percent versus 11 percent), pyrexia (13 percent versus 6 percent), chest discomfort (8 percent versus 6 percent), abdominal pain (7 percent versus 5 percent) and vomiting (6 percent versus 4 percent).
The most common adverse events reported over three treatment cycles with Cayston or TIS, respectively, were cough (70.
Gilead Wins Conditional Marketing Authorization for Cayston
Moreover, the FDA approval of Cayston earlier this year is also a positive.
Contract awarded for award summary one time contract cayston ncd 1 box x 84 vials
PARI is the only nebulizer company that has demonstrated clinical success in trials for Xopenex, Brovana, DuoNeb, AccuNeb, Perforomist, TOBI, and Cayston.
In October, Gilead announced positive data from its head-to-head Phase III clinical trial of Cayston versus tobramycin inhalation solution in cystic fibrosis patients with P.
Truvada, Viread, Hepsera, Emtriva, AmBisome, Letairis, Cayston and Ranexa are registered trademarks of Gilead Sciences, Inc.
In March 2010, the FDA approved Gilead Sciences' Cayston to treat Pseudomonas aeruginosa infections in CF patients.